Found: 10
Select item for more details and to access through your institution.
Safety and Tolerability of 60 Weeks' Extended Efalizumab Therapy in Patients with Chronic Moderate to Severe Plaque Psoriasis.
- Published in:
- Psoriasis Forum, 2007, n. 1, p. 28, doi. 10.1177/247553030713a00105
- By:
- Publication type:
- Article
Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial.
- Published in:
- Drug Safety, 2008, v. 31, n. 8, p. 715, doi. 10.2165/00002018-200831080-00008
- By:
- Publication type:
- Article
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial.
- Published in:
- 2006
- By:
- Publication type:
- Other
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
- Published in:
- International Journal of Dermatology, 2003, v. 42, n. 3, p. 224, doi. 10.1046/j.1365-4362.2003.01793.x
- By:
- Publication type:
- Article
Efalizumab for the Treatment of Psoriatic Arthritis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2007, v. 11, n. 2, p. 57, doi. 10.2310/7750.2007.00006
- By:
- Publication type:
- Article
Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2005, v. 9, n. 6, p. 313, doi. 10.1007/s10227-005-0117-0
- By:
- Publication type:
- Article
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome.
- Published in:
- Dermatology Reports, 2011, v. 3, n. 3, p. 125, doi. 10.4081/dr.2011.e55
- By:
- Publication type:
- Article
Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma.
- Published in:
- Oncologist, 2014, v. 19, n. 8, p. 790, doi. 10.1634/theoncologist.2014-0003
- By:
- Publication type:
- Article
First‐line atezolizumab monotherapy in patients with advanced BRAF<sup>V600</sup> wild‐type melanoma.
- Published in:
- Pigment Cell & Melanoma Research, 2021, v. 34, n. 5, p. 973, doi. 10.1111/pcmr.12960
- By:
- Publication type:
- Article
Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.
- Published in:
- Drug Safety, 2022, v. 45, n. 12, p. 1491, doi. 10.1007/s40264-022-01248-2
- By:
- Publication type:
- Article